1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Antimicrobial Susceptibility Testing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Importance of antimicrobial susceptibility testing in medical decision-making
5.1.1.2. Favorable government initiatives aiming to combat and prevent infectious diseases
5.1.2. Restraints
5.1.2.1. High cost of antimicrobial susceptibility kits and lack of skilled professionals
5.1.3. Opportunities
5.1.3.1. Ongoing research on nanoparticles-based antimicrobial susceptibility testing
5.1.3.2. Introduction of new genomic identification methods and launch of antimicrobial susceptibility test kits
5.1.4. Challenges
5.1.4.1. Incidence of product recalls and strict regulations regarding antimicrobial susceptibility testing commercialization
5.2. Market Segmentation Analysis
5.2.1. Product Type: Advancement in the automated tools and consumables for early diagnosing and treatment of the infectious diseases
5.2.2. Method: Development of qualitative AST techniques with increased accuracy of the tests
5.2.3. Type: Significant advancements in antifungal susceptibility testing due to heightened awareness of invasive fungal infections
5.2.4. Application: Rapid and extreme utilization of the AST in clinical diagnostics and drug discovery and development
5.2.5. End-User: Extensive use of AST in hospitals and diagnostic laboratories
5.3. Market Trend Analysis
5.3.1. Government programs and significant research activities to develop antimicrobial susceptibility tests in the Americas.
5.3.2. Emphasis on the antibiotic susceptibility testing research and development programmes to treat and diagnose highly prevalent communicable diseases in APAC
5.3.3. Significant funding for antibiotic susceptibility testing and support from regulatory agencies in the EMEA region.
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Antimicrobial Susceptibility Testing Market, by Product Type
6.1. Introduction
6.2. Automated Products
6.3. Consumables
6.4. Manual Products
6.5.1. Minimum Inhibitory Concentration (MIC) Strips
6.5.2. Susceptibility Discs
6.5.3. Susceptibility Plates
7. Antimicrobial Susceptibility Testing Market, by Method
7.1. Introduction
7.2. Agar Dilution
7.3. Disks Diffusion
7.4. ETEST
7.5. Genotyping Methods
7.6. Rapid Automation Method
8. Antimicrobial Susceptibility Testing Market, by Type
8.1. Introduction
8.2. Antibacterial Susceptibility Testing
8.3. Antifungal Susceptibility Testing
8.4. Antiparasitic Susceptibility Testing
9. Antimicrobial Susceptibility Testing Market, by Application
9.1. Introduction
9.2. Clinical Diagnostics
9.3. Drug Discovery & Development
9.4. Epidemiology
10. Antimicrobial Susceptibility Testing Market, by End-User
10.1. Introduction
10.2. Contract Research Organizations
10.3. Hospital & Diagnostic Centers
10.4. Pharmaceutical & Biotechnology
10.5. Research & Academic Institutes
11. Americas Antimicrobial Susceptibility Testing Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antimicrobial Susceptibility Testing Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Bio-Rad Acquires Curiosity Diagnostics
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. JMI Laboratories and bioMérieux Enter Antimicrobial Resistance Diagnostics Partnership
14.3.2.2. FASTinov Collaborates With Beckman Coulter Life Sciences To Bring Ultra-Rapid 2h-AST Disruptive Technology To Clinical Microbiology Laboratories
14.3.2.3. BD Enters Commercial Collaboration With Accelerate Diagnostics
14.3.3. New Product Launch & Enhancement
14.3.3.1. Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
14.3.3.2. Sysmex Launches World’s First Point-of-Care Testing System in Europe to Detect Antimicrobial Susceptibility in Just 30 Minutes
14.3.4. Investment & Funding
14.3.4.1. Strathclyde spin-out Microplate dx secures GBP 2.5 million in funding
14.3.4.2. Pattern Bioscience Secures USD 28.7 Million in Series C Financing
14.3.4.3. Resistell raises CHF 8.5 million to complete clinical trials for antibiotic susceptibility testing
14.3.4.4. Avails Medical, A Developer 0f Automated and Fully Electrical Antibiotic Susceptibility Testing (East) has Announced the Transition to The Next Phase of Its Carb-X Grant.
14.3.5. Award, Recognition, & Expansion
14.3.5.1. Gradientech Welcomes Investment From Commercial Partner
14.3.5.2. bioMérieux’s Submits Vitek Reveal to FDA for Clearance
14.3.5.3. Selux Diagnostics Secures FDA Approval For Its Rapid Antibiotic Susceptibility Test
14.3.5.4. FDA clears rapid antibiotic susceptibility test
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Accelerate Diagnostics, Inc.
15.1.2. Alifax S.r.l.
15.1.3. Becton, Dickinson and Company
15.1.4. Bio-Rad Laboratories, Inc.
15.1.5. BIOANALYSE Tıbbi Malz. San. ve Tic. Ltd. Sti.
15.1.6. BioMérieux SA
15.1.7. Biosafe Ltd.
15.1.8. Bruker Corporation
15.1.9. Creative Diagnostics
15.1.10. Danaher Corporation
15.1.11. ELITech Group SAS
15.1.12. Erba Lachema s.r.o.
15.1.13. Eurofins Scientific SE
15.1.14. F. Hoffmann-La Roche AG
15.1.15. Genefluidics, Inc.
15.1.16. Himedia Laboratories Private Limited
15.1.17. INTEGRA Biosciences AG
15.1.18. Laboratorios Conda, S.A.
15.1.19. Launch Diagnostics Limited
15.1.20. Leading Biology, Inc.
15.1.21. Liofilchem S.r.l.
15.1.22. Mast Group Ltd.
15.1.23. MP Biomedicals, LLC
15.1.24. Pfizer Inc.
15.1.25. Qiagen N.V.
15.1.26. QuantaMatrix Inc.
15.1.27. Rapid Test Methods Ltd.
15.1.28. Resistell AG
15.1.29. Synoptics Group
15.1.30. Thermo Fisher Scientific Inc.
15.1.31. Zhuhai DL Biotech Co., Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
